Is antiproliferative effect of HSP90 inhibitor Y306zh against pancreatic cancer mediated by interruption of AKT and MAPK signaling pathways?
Y306zh, a novel HSP90 inhibitor, interrupts ATP binding to HSP90 and disrupts HSP90-p23 interaction, and eventually inhibits the growth of PC cells.
The Frontal Assessment Battery did not discriminate subjects with frontotemporal lobar degeneration from those with Alzheimer disease, though certain subtests may be helpful in differential diagnosis.